CD44 positive and sorafenib insensitive hepatocellular carcinomas respond to the ATP-competitive mTOR inhibitor INK128

The mTOR pathway is activated in about 50% of patients with hepatocellular carcinoma (HCC). In an effort to identify new pathways and compounds to treat advanced HCC, we considered the ATP-competitive mTOR inhibitor INK128. ATP-competitive mTOR inhibitors attenuate both mTORC1 and mTORC2. INK128 was...

Descripción completa

Detalles Bibliográficos
Autores principales: Badawi, Mohamed, Kim, Jihye, Dauki, Anees, Sutaria, Dhruvitkumar, Motiwala, Tasneem, Reyes, Ryan, Wani, Nissar, Kolli, Shamalatha, Jiang, Jinmai, Coss, Christopher C., Jacob, Samson T., Phelps, Mitch A., Schmittgen, Thomas D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995255/
https://www.ncbi.nlm.nih.gov/pubmed/29899840
http://dx.doi.org/10.18632/oncotarget.25430

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995255/
https://www.ncbi.nlm.nih.gov/pubmed/29899840
http://dx.doi.org/10.18632/oncotarget.25430

Ejemplares similares